CORRECTION - Obagi Medical and Platinum Dermatology Partners Announce Collaboration in the ALOHA Program to Drive Real-World Evidence for Obagi® saypha® MagIQ(TM)
MWN-AI** Summary
Obagi Medical, a prominent name in physician-dispensed skincare, has partnered with Platinum Dermatology Partners to launch the Aesthetics Leadership with Obagi’s Hyaluronic Acid (ALOHA) Program. This initiative aims to collect real-world evidence regarding the safety and efficacy of Obagi’s saypha® MagIQ™, a new injectable developed using Croma-Pharma GmbH’s proprietary MACRO Core Technology. This technology ensures that the hyaluronic acid matrix used in the filler provides natural-looking results and high usability.
Michael Pennington, CEO and Co-founder of Platinum Dermatology Partners, emphasized the collaboration's alignment with their ethos of advancing aesthetic medicine through clinical research. By integrating the experience of their injectors who work with patients daily, the ALOHA Program is expected to translate clinical data into practical applications in various dermatology settings.
The program involves a structured clinical initiative where Platinum’s providers gain hands-on experience with Obagi’s products, aiming to enhance patient satisfaction and bolster the doctor-patient relationship. Key findings from the study will be shared at Platinum’s upcoming September summit in Dallas and other industry conferences, showcasing the real-world impact of the newly introduced injectable.
Drew Fine, U.S. General Manager of the Professional Channel at Obagi, highlighted that this partnership is a strategic move towards launching the injectable on a foundation of solid clinical evidence and integrated patient outcomes. The ALOHA Program reflects Obagi’s commitment to innovative products across skincare and injectable aesthetics.
This collaboration marks an important step for both Obagi Medical and Platinum Dermatology Partners, reinforcing their shared ambition to enhance dermatological care and improve treatment outcomes through evidence-based practices.
MWN-AI** Analysis
The recent collaboration between Obagi Medical and Platinum Dermatology Partners for the ALOHA Program marks a significant development in the skincare and aesthetics market. With industry innovation at the forefront, this partnership aims to validate the clinical effectiveness of Obagi saypha® MagIQ™ through real-world evidence, which is essential in a market increasingly driven by data transparency and patient satisfaction.
Investors should keenly watch Waldencast plc (NASDAQ: WALD), the parent company of Obagi Medical. The collaboration not only adds credibility to Waldencast’s product offerings but also sets a precedent for future partnerships within the aesthetics sector. The strategic choice of Platinum Dermatology Partners as a launch partner, given its extensive network and reputation, could translate to a competitive advantage, driving both brand awareness and product adoption.
The ALOHA program emphasizes robust clinical data and real-world application, allowing for a deeper understanding of patient experiences and outcomes. This emphasis on patient satisfaction aligns perfectly with current market trends prioritizing personalized and effective skincare solutions. Key industry presentations planned for this September and subsequent conferences will further boost visibility and foster trust in the new product.
With a background of rapid growth—Obagi being recognized as the fastest-growing professional skincare brand in the U.S. in 2024—this partnership has the potential to exponentially elevate Waldencast’s market position. Investors should consider the implications of such collaborations on Waldencast's stock performance, especially as the aesthetics market expands and consumer demand for proven, innovative treatments grows.
In conclusion, as the healthcare landscape continues to evolve, the success of the ALOHA program could serve as a bellwether for future innovations in the skincare industry. Stakeholders should keep a close watch on updates from this partnership, as they may present both challenges and opportunities within the marketplace.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
In a release issued under the same headline earlier today by Waldencast plc (NASDAQ: WALD), please note that the quote by Michael Pennington in paragraph 3 was incorrect. The corrected release follows:
NEW YORK and DALLAS, Jan. 26, 2026 (GLOBE NEWSWIRE) -- Obagi Medical, a leading innovator in physician-dispensed skincare and aesthetic solutions and part of Waldencast plc (NASDAQ: WALD) (“Waldencast” or the “Company”), today announced Platinum Dermatology Partners as the launch partner for the Aesthetics Leadership with Obagi’s Hyaluronic Acid (ALOHA) Program.
Platinum will help generate real-world data to translate the clinical safety and efficacy demonstrated in FDA pivotal trials into everyday practice across multiple trials and evaluation programs.
“This collaboration with Obagi very much matches our objectives and ethos to expand our capabilities in clinical research to advance the highest level of aesthetic medicine,” said Michael Pennington, Chief Executive Officer and Co-founder of Platinum Dermatology Partners. “Our injectors treat patients every day. That experience matters. This is the kind of work we should be doing. Obagi is thinking differently about product development, and that aligns with how we approach patient care.”
The ALOHA Real-World Program is designed to give Platinum providers hands-on experience with Obagi saypha MagIQ while evaluating complete Obagi protocols. This approach aims to drive patient satisfaction and strengthen relationships between patients and their Platinum providers. The program includes a real-world clinical initiative supplemented by a structured evaluation process across multiple Platinum practices and providers, with standardized data capture.
Platinum will present initial findings at this September's annual Platinum Summit in Dallas, highlighting the benefits of the new product and its protocols within the Platinum network. Results will also be presented at key industry conferences to demonstrate the real-world impact of introducing this innovative injectable across Platinum’s practices.
“Partnering with Platinum is a clear statement of our intent to launch this new injectable on a foundation of robust clinical evidence, education, and integrated patient outcomes,” said Drew Fine, U.S. General Manager, Professional Channel. “The ALOHA program will serve as a platform for a differentiated launch strategy and underscore Obagi Medical’s commitment to delivering innovative products across every facet of skincare and now injectable aesthetics.”
Obagi® saypha® MagIQ™, developed by Croma-Pharma GmbH, utilizes proprietary MACRO Core Technology to create a stable three-dimensional hyaluronic acid matrix. This technology is designed to deliver natural-looking results with category-leading performance, including high usable HA content upon injection, consistent gel distribution, and a predictable injection force and swelling profile1.
For more information about ALOHA, visit https://obagi-professional.com/
About Obagi Medical
Obagi Medical is an industry-leading, advanced skincare line rooted in research and skin biology, with a legacy of 35+ years of experience. Initially known for its leadership in the treatment of hyperpigmentation with the Obagi Nu-Derm® System, Obagi Medical products are designed to address a variety of skin concerns, including premature aging, photodamage, skin discoloration, acne, and sun damage. As the fastest-growing professional skincare brand in the U.S. in 2024,2 Obagi Medical empowers individuals to achieve healthy, beautiful skin. More information about Obagi Medical is available on the brand's website, https://www.obagi.com.
About Platinum Dermatology Partners
Headquartered in Dallas, Texas, Platinum Dermatology Partners exists to empower the practice of exceptional dermatology through its vast resources and differentiated culture. Today, Platinum spans over 120 locations and nearly 400 providers across Arizona, California, Florida, Nevada, and Texas. Through Platinum’s differentiated, physician-driven model, the company creates a collaborative group practice setting with a focus on partnering with the most reputable physicians and providers seeking to elevate not only the patient care delivered but also benefit the specialty of dermatology at large. For more information about Platinum Dermatology Partners, please visit www.platinumderm.com.
About Waldencast plc
Founded by Michel Brousset and Hind Sebti, Waldencast’s ambition is to build a global best-in-class beauty and wellness operating platform by developing, acquiring, accelerating, and scaling conscious, high-growth purpose-driven brands. Waldencast’s vision is fundamentally underpinned by its brand-led business model that ensures proximity to its customers, business agility, and market responsiveness, while maintaining each brand’s distinct DNA. The first step in realizing its vision was the Business Combination. As part of the Waldencast platform, its brands will benefit from the operational scale of a multi-brand platform; the expertise in managing global beauty brands at scale; a balanced portfolio to mitigate category fluctuations; asset light efficiency; and the market responsiveness and speed of entrepreneurial indie brands. For more information please visit: https://ir.waldencast.com.
Media Contact:
obagi@behrmancesa.com
Source: Waldencast plc
- Puljic A, Frank K, Cohen J, Otto K, Mayr J, Hugh-Bloch A, Kuroki-Hasenöhrl, D. A Scientific Framework for Comparing Hyaluronic Acid Filler Crosslinking Technologies. Gels. 2025; 11(7):487
- *Among the Top 10 Professional Skin Care Brands in the U.S., According to Kline’s 2024 Global Professional Skin Care Series (China, Europe and the U.S.)
FAQ**
How does Waldencast Acquisition Corp. WALD plan to leverage the partnership with Platinum Dermatology Partners to enhance the credibility and market presence of Obagi Medical’s ALOHA Program in the aesthetics sector?
What specific metrics will Waldencast Acquisition Corp. WALD and Platinum Dermatology Partners use to evaluate the success of the ALOHA Program in terms of clinical outcomes and patient satisfaction?
In what ways does Waldencast Acquisition Corp. WALD aim to differentiate Obagi Medical’s products in the competitive landscape of skincare and aesthetics, particularly with the introduction of Obagi saypha MagIQ?
What role does real-world data generated in the ALOHA Program play in Waldencast Acquisition Corp. WALD's strategy for product development and strategic positioning within the skincare market?
**MWN-AI FAQ is based on asking OpenAI questions about Waldencast Acquisition Corp. (NASDAQ: WALD).
NASDAQ: WALD
WALD Trading
3.9% G/L:
$1.60 Last:
8,798 Volume:
$1.56 Open:
